Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi Pasteur’s Dengvaxia to be used in Philippines immunisation programme

Sanofi Pasteur’s Dengvaxia to be used in Philippines immunisation programme

5th April 2016

Sanofi Pasteur has announced that its tetravalent dengue vaccine Dengvaxia is being used in a groundbreaking immunisation programme being launched in the Philippines.

The scheme represents the world's first public dengue immunisation programme, with Dengvaxia to be used to vaccinate one million students from 6,000 public schools this year in three highly dengue-endemic regions of the country.

Dengvaxia was approved for use in individuals between the ages of nine and 45 for the prevention of dengue fever caused by all four disease serotypes in December 2015. It has been shown to be able to prevent eight in ten dengue hospitalisations and up to 93 percent of severe dengue cases.

Asia currently bears 70 percent of the world's dengue burden, with the Philippines alone accounting for 200,000 cases of dengue in 2013.

Olivier Charmeil, executive vice-president of Sanofi Pasteur, said: "Ensuring access to this approved vaccine in a public immunisation programme attests to the Filipino health authority's commitment to add this new dengue prevention tool to their integrated disease management strategy."

Dengvaxia is also registered in Mexico, Brazil and El Salvador, and is the first vaccine licensed for the prevention of dengue anywhere in the world.ADNFCR-8000103-ID-801815938-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.